ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $550.40 ($543.54–$554.84, $5.23M total) across 11 trades on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete information is the disclosed open-market sale size ($5.23M), share count (9,500 across 11 trades), and the stated use of a pre-arranged 10b5-1 plan.
Market read
This provides a fresh, timestamped insider-selling datapoint for UTHR, but it lacks any new operational or financial guidance catalyst.
What to watch
Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the signal is typically weaker—watch for subsequent filings (additional sales/buys) and next fundamental catalysts.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR) by CEO/Chair Martine Rothblatt.
Ticker impact
United Therapeutics Form 4 shows CEO/Chair Martine Rothblatt sold $5.23M of UTHR shares via an open-market transaction under a 10b5-1 plan on 2026-06-25.
Likely limited, short-lived sentiment impact; follow-through depends on broader tape/earnings context rather than this filing alone.
The filing is primary-source and time-stamped, but it specifies a pre-arranged 10b5-1 plan and provides no new company fundamentals (no guidance, trial, deal, or regulatory action).
Market effects
Minimal; this is company-specific insider activity with no sector-wide catalyst described.
Minimal; no macro/regional linkage is provided beyond the US-listed issuer.
Minimal; no international transaction or regulatory action is mentioned.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/portfolio management rather than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction; CEO/Chair sold shares on 2026-06-25 under a 10b5-1 plan.
- insiderROTHBLATT MARTINE A
Chairperson & CEO who executed the open-market sale disclosed in the Form 4.
